“Clinical Response and Safety of Alternating Daily Dosage of Crizotinib Due to Side Effects in Advanced NSCLC Patient Harboring ROS1-Rearrangement: A Case Report”. 2023. Jurnal Respirologi Indonesia 43 (2): 111-15. https://doi.org/10.36497/jri.v43i2.201.